Bispecific antibody · Immune activation, directed at prostate-specific membrane antigen (FOLH1) and CD3 (CD3E) · developed by Janux Therapeutics
JANX014 is a dual-masked T-cell engager with one arm binding prostate-specific membrane antigen (PSMA) on tumor cells and another arm binding CD3 on cytotoxic T-lymphocytes. Both binding domains are masked by cleavable peptide linkers that tumor-specific proteases remove at the tumor site. It is being studied in prostate cancer, including metastatic castration-resistant prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07545811 | Phase 1 | Prostate Cancer | Recruiting | JANX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate CancerProstate Cancer
Updated Oct 18, 2026. Something wrong or missing? Report it on the JANX page.
See JANX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JANX catalysts and pipeline →